Altrova Health Reports Third Quarter Fiscal 2026 Financial Results

Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Careers Services Services Press Release Distribution News Service Overview Global Distribution Additional News Services AI Disclosure Intelligence SEDAR+ About SEDAR+ SEDAR+ Resources EDGAR EDGAR Service Overview EDGAR Resources Webcasting and Conference Calling Newsroom Newsroom Newsroom Newswire Guidelines Sign Up for News Integrate Blog Contact Altrova Health Reports Third Quarter Fiscal 2026 Financial Results August 31, 2026 6:37 PM EDT | Source: Altrova Health Inc. Toronto, Ontario--(Newsfile Corp. - August 31, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) (" Altrova Health " or the " Company ") today announced its financial results for the three and nine-month periods ended June 30, 2026 (" Q3 Fiscal 2026 "). The Company's condensed interim consolidated financial statements and related management's discussion and analysis for the period (collectively, the " Interim Filings ") have been filed under the Company's profile on SEDAR+ at www.sedarplus.ca . All dollar amounts in this news release are expressed in Canadian dollars unless otherwise indicated. Q3 Fiscal 2026 Highlights: First commercial revenue: nine-month revenue of $112,000, up from $15,551 in the prior comparative period, as distribution and commercialization initiatives put in place over the past year began converting into recurring commercial activity for the first time in the Company's history. Expanding distribution network: continued NIRLAB SA (" NIRLAB ") device sales, expanded partnerships with Indigenous and First Nations communities, and a planned relaunch of the Drug Lab 118 Ltd. rapid detection strip portfolio. Completed rebrand and cross-border uplisting: shares now trade as Altrova Health Inc. on the CSE (ROVA) and OTCQB (ATVHF), aligning the Company's US and Canadian trading identity with its healthcare platform. Lower discretionary costs: general and administrative, investor relations and professional fees each declined year-over-year even as the Company scaled its commercial operations. Management Commentary "This quarter marks an important turning point for Altrova," said Geoff Benic, Chief Executive Officer of Altrova Health. "Generating our first meaningful product revenue tells us that the distribution relationships and commercial partnerships we have built over the past year are starting to convert into real activity. Combined with a refreshed board and leadership team, we believe we are building the foundation to carry that momentum forward." "This quarter reflects the direction the board wants to see from this management team," said The Hon. Tony Clement, Chairman of the Board of Altrova Health. "The Company is beginning to show real commercial progress, and it's doing so with the financial discipline and leadership strength this stage of growth requires. The board's role now is to keep holding management to that standard." Financial Summary Selected results for the nine-month period ended June 30, 2026, compared to the nine-month period ended June 30, 2025: Results of Operations Nine Months Ended June 30, 2026 Nine Months Ended June 30, 2025 Revenue $ 112,000 $ 15,551 Gross Profit $ 62,488 $ 9,702 Gross Margin 55.8% 62.4% Net loss and comprehensive loss $ (2,351,996 ) $ (1,098,177 ) Altrova's third fiscal quarter results reflect a company translating a year of distribution and commercialization work into measurable commercial output for the first time. Revenue grew to $112,000 for the nine-month period, as sales through the Company's NIRLAB channels moved from occasional transactions toward a more consistent flow of commercial activity. Gross profit followed the same trajectory, rising to $62,488, providing evidence that the growth in revenue is carrying through to the product level, and not simply widening the top line. Gross margin moderated to 55.8% from 62.4%, consistent with the shift from a small number of early-stage transactions in the prior comparative period to broader-based commercial sales in the current year. Net loss and comprehensive loss increased to $2,351,996 from $1,098,177. More than 60% of that increase is attributable to two non-cash items rather than the Company's core operating costs: a $330,640 one-time charge recognized upon the mutual termination of an exclusive license agreement in May 2026, representing the write-off of that license's remaining carrying value, not a cash expenditure, and a $463,785 increase in non-cash share-based compensation tied to stock option vesting. The remainder of the increase reflects higher management and consulting fees supporting the